FATE THERAPEUTICS INCFATE
ASignal's systematic analysis rates FATE as Neutral.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on FATE
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.80)
- Low debt-to-equity ratio (0.49x) indicating manageable leverage
- High current and quick ratios (4.85x, 4.75x) suggesting solid short-term liquidity
- Positive revenue growth (9.2% YoY) in a high-risk biotech context
- Cash-rich balance sheet with $153.77M in cash against $75.67M in debt
- Negative MACD histogram and price momentum indicating ongoing downtrend
- Price trading below both SMA20 and SMA50, signaling technical weakness
- Extremely high price-to-sales (40.24x) and EV-to-revenue (27.29x) valuations
- Deeply negative operating margin (-1495.39%) and return on equity (-60.75%)
- Negative free cash flow (-$48.66M) and operating cash flow (-$101.94M)
- No news coverage or Reddit mentions, suggesting low market attention or sentiment data
See the full verdict on FATE
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes FATE
Most investors never get a second opinion, let alone several. ASignal runs FATE past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.